An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells
- PMID: 10962448
An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells
Abstract
Recombinant T-cell receptors with antibody-like specificity for tumor-associated antigens are successfully used to direct the cytolytic activity of T cells toward tumor cells. Clinical application, however, needs to comply with the low immunogenicity of the recombinant receptor, efficient gene transfer into peripheral blood T cells, and enrichment of receptor-grafted cells. Here, we address these issues and describe an entirely humanized immune receptor for use in adoptive immunotherapy of colorectal carcinoma. The receptor consists of a single-chain antibody (scFv) binding domain specific for carcinoembryonic antigen (CEA), the IgG hinge and CH2/CH3 (Fc) joining region, and the transmembrane and intracellular CD3 zeta signaling chain. To express the receptor in peripheral blood T cells, both GALV envelope and MuLV 4070A pseudotyped retrovirus turned out to be equally efficient, with transduction efficiencies of about 5% to 40%, depending on the lymphocyte donor. Furthermore, receptor-grafted T cells could be 2- to 6-fold enriched by magnetic activated cell sorting, utilizing an antibody directed to the extracellular IgG domain of the receptor. Upon co-culture with CEA(+) tumor cells, receptor-grafted T cells are specifically and efficiently activated to cytolysis and IFN-gamma secretion, demonstrating their feasibility for the adoptive immunotherapy of CEA(+) carcinomas.
Copyright 2000 Wiley-Liss, Inc.
Similar articles
-
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.Cancer Res. 2001 Mar 1;61(5):1976-82. Cancer Res. 2001. PMID: 11280755
-
Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.Clin Cancer Res. 1999 Dec;5(12):3928-41. Clin Cancer Res. 1999. PMID: 10632322
-
Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.J Immunol. 2001 Dec 1;167(11):6123-31. doi: 10.4049/jimmunol.167.11.6123. J Immunol. 2001. PMID: 11714771
-
Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA.Anticancer Res. 2000 Nov-Dec;20(6A):4067-71. Anticancer Res. 2000. PMID: 11131674 Review.
-
The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy.Curr Gene Ther. 2002 May;2(2):211-26. doi: 10.2174/1566523024605573. Curr Gene Ther. 2002. PMID: 12109217 Review.
Cited by
-
CARs in chronic lymphocytic leukemia -- ready to drive.Curr Hematol Malig Rep. 2013 Mar;8(1):60-70. doi: 10.1007/s11899-012-0145-y. Curr Hematol Malig Rep. 2013. PMID: 23225251 Free PMC article. Review.
-
Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells.Am J Pathol. 2013 Jun;182(6):2121-31. doi: 10.1016/j.ajpath.2013.02.017. Epub 2013 Apr 2. Am J Pathol. 2013. PMID: 23562272 Free PMC article.
-
The promise and potential pitfalls of chimeric antigen receptors.Curr Opin Immunol. 2009 Apr;21(2):215-23. doi: 10.1016/j.coi.2009.02.009. Epub 2009 Mar 25. Curr Opin Immunol. 2009. PMID: 19327974 Free PMC article. Review.
-
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.Front Biosci (Schol Ed). 2012 Jan 1;4(2):520-31. doi: 10.2741/282. Front Biosci (Schol Ed). 2012. PMID: 22202074 Free PMC article. Review.
-
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.Blood. 2010 Aug 19;116(7):1035-44. doi: 10.1182/blood-2010-01-043737. Epub 2010 May 3. Blood. 2010. PMID: 20439624 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources